ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has strongly refuted recent reports claiming an increase in the prices of essential medicines, including insulin and life-saving drugs. In a statement, DRAP clarified that no price revisions have been made for essential medicines in recent months.
The regulatory body clarified that the prices cited in the news reports referred to the Maximum Retail Prices (MRPs) printed on medicine packs and insulin delivery devices, such as the HumaPen Ergo II (used for 4-5 years), which were manufactured in 2024 or 2025. These prices were misrepresented as a recent price hike, the Authority noted.
DRAP emphasized that there has been no new approval for a price increase for any products listed on the National Essential Medicines List (NEML), and pharmaceutical manufacturers are prohibited from implementing unilateral price hikes. The Authority assured the public that essential medicines would remain affordable and accessible.
In addition to addressing price concerns, DRAP also provided reassurance regarding the supply chain. The Authority confirmed that it had conducted a thorough review of the supply chain for medicines and medical devices, finding it satisfactory for the coming months. Approximately 85% of medicines consumed in Pakistan are locally manufactured and remain unaffected by disruptions in Middle Eastern airspace or sea routes.
To further strengthen the resilience of the supply chain, DRAP issued advisories to all manufacturers, advising them to adopt “multiple sourcing strategies” and to ensure geographically diverse supply channels to prevent any future shortages due to temporary disruptions.
The Authority urged news outlets to verify any information regarding medicines with DRAP before publication to avoid spreading misinformation and creating unnecessary panic. DRAP reaffirmed its commitment to regulating and ensuring uninterrupted access to safe, effective, and quality-assured therapeutic goods for the people of Pakistan.
In its final note, DRAP reminded the public that it continues to prioritize the accessibility and affordability of essential medicines and remains vigilant in its regulatory oversight.
Read also: Pakistan sets medical milestone with first robotic surgery via telemedicine
